224 related articles for article (PubMed ID: 27631310)
1.
Luan X; Huang Y; Gao S; Sun X; Wang S; Ma L; Teng X; Lu H; Yu J; Yuan S
Eur J Nucl Med Mol Imaging; 2016 Dec; 43(13):2336-2342. PubMed ID: 27631310
[TBL] [Abstract][Full Text] [Related]
2. Tumor angiogenesis at baseline identified by
Wei Y; Qin X; Liu X; Zheng J; Luan X; Zhou Y; Yu J; Yuan S
J Transl Med; 2022 Feb; 20(1):63. PubMed ID: 35109866
[TBL] [Abstract][Full Text] [Related]
3. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
4. A pilot study imaging integrin αvβ3 with RGD PET/CT in suspected lung cancer patients.
Gao S; Wu H; Li W; Zhao S; Teng X; Lu H; Hu X; Wang S; Yu J; Yuan S
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):2029-37. PubMed ID: 26153145
[TBL] [Abstract][Full Text] [Related]
5. A Pilot Study of
Zhou Y; Gao S; Huang Y; Zheng J; Dong Y; Zhang B; Zhao S; Lu H; Liu Z; Yu J; Yuan S
Sci Rep; 2017 Jun; 7(1):2877. PubMed ID: 28588317
[TBL] [Abstract][Full Text] [Related]
6. Early Change in Metabolic Tumor Heterogeneity during Chemoradiotherapy and Its Prognostic Value for Patients with Locally Advanced Non-Small Cell Lung Cancer.
Dong X; Sun X; Sun L; Maxim PG; Xing L; Huang Y; Li W; Wan H; Zhao X; Xing L; Yu J
PLoS One; 2016; 11(6):e0157836. PubMed ID: 27322376
[TBL] [Abstract][Full Text] [Related]
7. Comparing the Diagnostic Potential of 68Ga-Alfatide II and 18F-FDG in Differentiating Between Non-Small Cell Lung Cancer and Tuberculosis.
Kang F; Wang S; Tian F; Zhao M; Zhang M; Wang Z; Li G; Liu C; Yang W; Li X; Wang J
J Nucl Med; 2016 May; 57(5):672-7. PubMed ID: 26719378
[TBL] [Abstract][Full Text] [Related]
8. (99m)Tc-3PRGD 2 SPECT/CT predicts the outcome of advanced nonsquamous non-small cell lung cancer receiving chemoradiotherapy plus bevacizumab.
Ma Q; Min K; Wang T; Chen B; Wen Q; Wang F; Ji T; Gao S
Ann Nucl Med; 2015 Jul; 29(6):519-27. PubMed ID: 25911312
[TBL] [Abstract][Full Text] [Related]
9. Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy.
Ohno Y; Koyama H; Yoshikawa T; Matsumoto K; Aoyama N; Onishi Y; Sugimura K
AJR Am J Roentgenol; 2012 Jan; 198(1):75-82. PubMed ID: 22194481
[TBL] [Abstract][Full Text] [Related]
10. Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.
Hyun SH; Ahn HK; Ahn MJ; Ahn YC; Kim J; Shim YM; Choi JY
AJR Am J Roentgenol; 2015 Sep; 205(3):623-8. PubMed ID: 26295651
[TBL] [Abstract][Full Text] [Related]
11. To Explore a Representative Hypoxic Parameter to Predict the Treatment Response and Prognosis Obtained by [
Li L; Wei Y; Huang Y; Yu Q; Liu W; Zhao S; Zheng J; Lu H; Yu J; Yuan S
Mol Imaging Biol; 2018 Dec; 20(6):1061-1067. PubMed ID: 29623510
[TBL] [Abstract][Full Text] [Related]
12. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
[TBL] [Abstract][Full Text] [Related]
13. Can an ¹⁸F-ALF-NOTA-PRGD2 PET/CT Scan Predict Treatment Sensitivity to Concurrent Chemoradiotherapy in Patients with Newly Diagnosed Glioblastoma?
Zhang H; Liu N; Gao S; Hu X; Zhao W; Tao R; Chen Z; Zheng J; Sun X; Xu L; Li W; Yu J; Yuan S
J Nucl Med; 2016 Apr; 57(4):524-9. PubMed ID: 26514171
[TBL] [Abstract][Full Text] [Related]
14. Dynamic contrast-enhanced perfusion area-detector CT assessed with various mathematical models: Its capability for therapeutic outcome prediction for non-small cell lung cancer patients with chemoradiotherapy as compared with that of FDG-PET/CT.
Ohno Y; Fujisawa Y; Koyama H; Kishida Y; Seki S; Sugihara N; Yoshikawa T
Eur J Radiol; 2017 Jan; 86():83-91. PubMed ID: 28027771
[TBL] [Abstract][Full Text] [Related]
15. Response Prediction Using
Hu X; Zhou T; Ren J; Duan J; Wu H; Liu X; Mu Z; Liu N; Wei Y; Yuan S
J Nucl Med; 2023 Apr; 64(4):625-631. PubMed ID: 36229183
[TBL] [Abstract][Full Text] [Related]
16. Prognostic importance of
Kanyilmaz G; Benli Yavuz B; Aktan M; Sahin O
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):20-26. PubMed ID: 31668790
[TBL] [Abstract][Full Text] [Related]
17. Standard uptake value and metabolic tumor volume of ¹⁸F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer.
Huang W; Zhou T; Ma L; Sun H; Gong H; Wang J; Yu J; Li B
Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1628-35. PubMed ID: 21617977
[TBL] [Abstract][Full Text] [Related]
18. Is post-treatment standardized uptake value a prognostic factor in unresectable non-small cell lung carcinoma?
Yılmaz U; Yasar Z; Korkmaz E; Yalcın B; Koparal H; Ozbilek E
Med Glas (Zenica); 2017 Aug; 14(2):204-210. PubMed ID: 28698535
[TBL] [Abstract][Full Text] [Related]
19. Early metabolic response on 18F-fluorodeoxyglucose-positron-emission tomography/computed tomography after concurrent chemoradiotherapy for advanced stage III non-small cell lung cancer is correlated with local tumor control and survival.
Jeong JU; Chung WK; Nam TK; Song JY; Yoon MS; Kim YC; Kim KS; Oh IJ; Ban HJ; Kwon SY; Bom HS; Ahn SJ
Anticancer Res; 2014 May; 34(5):2517-23. PubMed ID: 24778069
[TBL] [Abstract][Full Text] [Related]
20. Predicting tumor responses and patient survival in chemoradiotherapy-treated patients with non-small-cell lung cancer using dynamic contrast-enhanced integrated magnetic resonance-positron-emission tomography.
Huang YS; Chen JL; Chen JY; Lee YF; Huang JY; Kuo SH; Yen RF; Chang YC
Strahlenther Onkol; 2019 Aug; 195(8):707-718. PubMed ID: 30610356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
